Literature DB >> 17017994

N-type calcium channel blockers: novel therapeutics for the treatment of pain.

C I Schroeder1, C J Doering, G W Zamponi, R J Lewis.   

Abstract

Highly selective Ca(v)2.2 voltage-gated calcium channel (VGCC) inhibitors have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Cone snail venoms provided the first drug in class with FDA approval granted in 2005 to Prialt (omega-conotoxin MVIIA, Elan) for the treatment of neuropathic pain. Since this pioneering work, major efforts underway to develop alternative small molecule inhibitors of Ca(v)2.2 calcium channel have met with varied success. This review focuses on the properties of the Ca(v)2.2 calcium channel in different pain states, the action of omega-conotoxins GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved Ca(v)2.2 calcium channel therapeutics, and finally the development of small molecules for the treatment of chronic pain.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17017994     DOI： 10.2174/157340606778250216

Source DB:  PubMed          Journal:  Med Chem        ISSN： 1573-4064            Impact factor:   2.745


  14 in total

Review 1.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.

Authors:  Polina Feldman; Rajesh Khanna
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

Review 3.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 4.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

5.  Intranasal Oxytocin Administration is Associated With Enhanced Endogenous Pain Inhibition and Reduced Negative Mood States.

Authors:  Burel R Goodin; Austen J B Anderson; Emily L Freeman; Hailey W Bulls; Meredith T Robbins; Timothy J Ness
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

6.  A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatement.

Authors:  Philip M Newton; Lily Zeng; Victoria Wang; Jacklyn Connolly; Melisa J Wallace; Chanki Kim; Hee-Sup Shin; Francesco Belardetti; Terrance P Snutch; Robert O Messing
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 7.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Involvement of Gi/o proteins and GIRK channels in the potentiation of morphine-induced spinal analgesia in acutely inflamed mice.

Authors:  Sara González-Rodríguez; Agustín Hidalgo; Ana Baamonde; Luis Menéndez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-26       Impact factor: 3.000

9.  Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.

Authors:  G Berecki; N L Daly; Y H Huang; S Vink; D J Craik; P F Alewood; D J Adams
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 10.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.

Authors:  Gerald W Zamponi; Joerg Striessnig; Alexandra Koschak; Annette C Dolphin
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.